(Q37641333)

21 August 2017

1 reference

title

The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus (English)

1 reference

21 August 2017

0 references

Barbara J Zarowitz

1

1 reference

21 August 2017

Christopher Conner

series ordinal

2

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

21 August 2017

1 reference

21 August 2017

volume

29

1 reference

21 August 2017

issue

12 Pt 2

1 reference

21 August 2017

page(s)

55S-67S

1 reference

Economic costs of diabetes in the U.S. In 2007.

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

What factors contribute to the inadequate control of elevated blood pressure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

A systematic review of adherence with medications for diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

An assessment of attitudes, behaviors, and outcomes of patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Treating diabetes to accepted standards of care: a 10-year projection of the estimated economic and health impact in patients with type 1 and type 2 diabetes mellitus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Nonadherence as a predictor of antidiabetic drug therapy intensification (augmentation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Hypoglycemia as a predictor of mortality in hospitalized elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Unrecognized Hypo- and Hyperglycemia in Well-Controlled Patients with Type 2 Diabetes Mellitus: The Results of Continuous Glucose Monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

The role of incretins in glucose homeostasis and diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Insights from the Liraglutide Clinical Development Program--the Liraglutide Effect and Action in Diabetes (LEAD) studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Obesity and undiagnosed diabetes in the U.S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Annual medical spending attributable to obesity: payer-and service-specific estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Dispelling myths and removing barriers about insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Treatment preferences and medication adherence of people with Type 2 diabetes using oral glucose-lowering agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Measuring beliefs about taking hypoglycaemic medication among people with Type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Intentional weight loss and mortality among overweight individuals with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Weight change in diabetes and glycemic and blood pressure control

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Deleterious effects of increased body weight associated with intensive insulin therapy for type 1 diabetes: increased blood pressure and worsened lipid profile partially negate improvements in life expectancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

The CORE Diabetes Model: Projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

Intensive glycemic control in the ACCORD and ADVANCE trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.PT2.55S

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.PT2.55S

1 reference

21 August 2017

1 reference